Duodenal Cancer Market Research Report – Forecast to 2027

Duodenal Cancer Market Research Report: By Type (Adenocarcinoma, Sarcoma, Neuroendocrine Tumors, Lymphoma), by Diagnosis (Colonoscopy, Capsule Endoscopy, Barium X-Ray, CT Scan, MRI), by Treatment (Surgery, Radiotherapy, Chemotherapy) – Forecast Till 2027

ID: MRFR/Pharma/4959-HCR | | Region: Global | 90 pages

Duodenal Cancer Market Scenario


The duodenal cancer market is expected to grow slowly over the forecast period. It is estimated that the duodenal cancer market is expected to register a CAGR ~ 3.2% during the forecast period of 2018–2023. Duodenal cancer, also known as the small bowel cancer, are caused in the duodenum area of the small intestine.


Numerous factors such as the growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.


Moreover, favorable healthcare expenditures boost the growth of the market. However, stringent government regulation for product approval and the high cost of the treatments may hamper the market growth during the assessment period.


Segmentation


The duodenal cancer market has been segmented into type, diagnosis, and treatment.


The market, on the basis of type, has been segmented into adenocarcinoma, sarcoma, neuroendocrine (carcinoid) tumors, and lymphoma.


The market, by diagnosis, has been segmented into endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.


The market, by treatment, has been segmented into surgery, radiotherapy, and chemotherapy.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The duodenal cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European duodenal cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The duodenal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The duodenal cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Bayer AG are some of the key players in the duodenal cancer market.


Regional Market Summary


Duodenal Cancer Market Share (%), by Region, 2017


Duodenal Cancer Market Share


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the duodenal cancer market owing to a well-developed healthcare sector, rising prevalence of rare and chronic disease and growing healthcare expenditure. According to an article published by, American Society of Clinical Oncology (ASCO) in January 2018, 67% of people diagnosed with duodenal cancer survive it for five years. Europe is expected to hold the second largest position in the duodenal cancer market. The market growth in this region is attributed to the growing prevalence of chronic diseases, availability of funds for research, and increasing healthcare expenditure. According to Cancer Research UK, 41,804 new cases of bowel cancer were reported in 2015 in the UK.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of diseases and increasing government funding for the healthcare sector. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Duodenal Cancer Market, by Type



  • Adenocarcinoma

  • Sarcoma

  • Neuroendocrine (carcinoid) tumors

  • Lymphoma


Duodenal Cancer Market, by Diagnosis



  • Endoscopy or Colonoscopy

  • Capsule Endoscopy

  • Barium X-Ray

  • CT Scan

  • MRI Scan

  • Other Tests


Duodenal Cancer Market, by Treatment



  • Surgery

  • Radiotherapy

  • Chemotherapy


Duodenal Cancer Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa

  • Middle East

  • Africa



Frequently Asked Questions (FAQ) :


Duodenal cancer market would achieve a valuation of 3.2% for the forecast period of 2020 to 2027.

The market could be boosted by favorable healthcare expenditure.

Duodenal cancer market growth would get cloistered a bit by its high expenditure.

The type-based segmentation has sarcoma, neuroendocrine (carcinoid) tumors, adenocarcinoma, and lymphoma.

The diagnosis segments are endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Duodenal Cancer Market, by Type

6.1 Introduction

6.2 Adenocarcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Sarcoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Neuroendocrine (carcinoid) tumors

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Lymphoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Duodenal Cancer Market, by Diagnosis

7.1 Introduction

7.2 Endoscopy or Colonoscopy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Capsule Endoscopy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Barium X-Ray

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 CT Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.6 MRI Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.7 Other Tests

Chapter 8. Global Duodenal Cancer Market, by Treatment

8.1 Introduction

8.2 Surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Radiotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Duodenal Cancer Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 AbbVie, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Pfizer Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Eli Lilly and Company

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bristol-Myers Squibb Company

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 F. Hoffman-La Roche Ltd.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Becton, Dickinson and Company

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Novartis AG

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Ipsen Biopharmaceuticals, Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Thermo Fisher Scientific

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Abbott

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 G E Healthcare

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Agilent Technologies, Inc.

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 AstraZeneca

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Boehringer Ingelheim International GmbH

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Bayer AG

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Duodenal Cancer Industry

Chapter 13. Appendix


LIST OF TABLES

Table 1 Global Duodenal Cancer Market Synopsis, 2020–2027

Table 2 Global Duodenal Cancer Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Duodenal Cancer Market, by Region, 2020–2027 (USD Million)

Table 4 Global Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 5 Global Duodenal Cancer Market, by Diagnosis, 2020–2027(USD Million)

Table 6 Global Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 7 North America: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 8 North America: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 9 North America: Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 10 US: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 11 US: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 12 US: Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 13 Canada: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 14 Canada: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 15 Canada: Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 16 South America: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 17 South America: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 18 South America: Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 19 Europe: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 20 Europe: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 21 Europe: Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 22 Western Europe: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 23 Western Europe: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 24 Western Europe: Duodenal Cancer Market, by Treatment, 2020–2027 (USD

Million)

Table 25 Eastern Europe: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 26 Eastern Europe: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 27 Eastern Europe: Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 28 Asia-Pacific: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 29 Asia-Pacific: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 30 Asia-Pacific: Duodenal Cancer Market, by Treatment, 2020–2027 (USD Million)

Table 31 Middle East & Africa: Duodenal Cancer Market, by Type, 2020–2027 (USD Million)

Table 32 Middle East & Africa: Duodenal Cancer Market, by Diagnosis, 2020–2027 (USD Million)

Table 33 Middle East & Africa: Duodenal Cancer Market, by Treatment, 2020–2027 (USD

Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Duodenal Cancer Market

Figure 3 Segmentation Market Dynamics for Global Duodenal Cancer Market

Figure 4 Global Duodenal Cancer Market Share, by Type, 2020

Figure 5 Global Duodenal Cancer Market Share, by Diagnosis, 2020

Figure 6 Global Duodenal Cancer Market Share, by Treatment, 2020

Figure 7 Global Duodenal Cancer Market Share, by Region, 2020

Figure 8 North America: Duodenal Cancer Market Share, by Country, 2020

Figure 9 Europe: Duodenal Cancer Market Share, by Country, 2020

Figure 10 Asia-Pacific: Duodenal Cancer Market Share, by Country, 2020

Figure 11 Middle East & Africa: Duodenal Cancer Market Share, by Country, 2020

Figure 12 Global Duodenal Cancer Market: Company Share Analysis, 2020 (%)

Figure 13 AbbVie, Inc.: Key Financials

Figure 14 AbbVie, Inc.: Segmental Revenue

Figure 15 AbbVie, Inc.: Geographical Revenue

Figure 16 Pfizer Inc.: Key Financials

Figure 17 Pfizer Inc.: Segmental Revenue

Figure 18 Pfizer Inc.: Geographical Revenue

Figure 19 Eli Lily and Company: Key Financials

Figure 20 Eli Lily and Company: Segmental Revenue

Figure 21 Eli Lily and Company: Geographical Revenue

Figure 22 Bristol-Myers Squibb Company: Key Financials

Figure 23 Bristol-Myers Squibb Company: Segmental Revenue

Figure 24 Bristol-Myers Squibb Company: Geographical Revenue

Figure 25 F. Hoffman-La Roche Ltd.: Key Financials

Figure 26 F. Hoffman-La Roche Ltd.: Segmental Revenue

Figure 27 F. Hoffman-La Roche Ltd.: Geographical Revenue

Figure 28 Becton, Dickinson and Company: Key Financials

Figure 29 Becton, Dickinson and Company: Segmental Revenue

Figure 30 Becton, Dickinson and Company: Geographical Revenue

Figure 31 Novartis AG: Key Financials

Figure 32 Novartis AG: Segmental Revenue

Figure 33 Novartis AG: Geographical Revenue

Figure 34 Ipsen Biopharmaceuticals, Inc.: Financials

Figure 35 Ipsen Biopharmaceuticals, Inc.: Segmental Revenue

Figure 36 Ipsen Biopharmaceuticals, Inc.: Geographical Revenue

Figure 37 Thermo Fisher Scientific: Key Financials

Figure 38 Thermo Fisher Scientific: Segmental Revenue

Figure 39 Thermo Fisher Scientific: Geographical Revenue

Figure 40 Abbott: Key Financials

Figure 41 Abbott: Segmental Revenue

Figure 42 Abbott: Geographical Revenue

Figure 43 G E Healthcare: Key Financials

Figure 44 G E Healthcare: Segmental Revenue

Figure 45 G E Healthcare: Geographical Revenue

Figure 46 Agilent Technologies, Inc.: Key Financials

Figure 47 Agilent Technologies, Inc.: Segmental Revenue

Figure 48 Agilent Technologies, Inc.: Geographical Revenue

Figure 49 AstraZeneca: Key Financials

Figure 50 AstraZeneca: Segmental Revenue

Figure 51 AstraZeneca: Geographical Revenue

Figure 52 Boehringer Ingelheim International GmbH: Key Financials

Figure 53 Boehringer Ingelheim International GmbH: Segmental Revenue

Figure 54 Boehringer Ingelheim International GmbH: Geographical Revenue

Figure 55 Bayer AG: Key Financials

Figure 56 Bayer AG: Segmental Revenue

Figure 57 Bayer AG: Geographical Revenue